• Rucaparib and PARP-Linked Cell Death: Evidence

  2026-10-08

  A source-grounded overview of Rucaparib (AG-014699) in DNA damage response research, covering PARP biology, conceptual applications, radiosensitization, transporter effects, evidence strength, and key limitations.

• CD36-Driven Immune Escape in AML

  2026-10-08

  A 2024 Cell Reports Medicine study identifies a non-canonical CD36 lipid-sensing program that enables acute myeloid leukemia cells to suppress T-cell activity and weaken decitabine responses. The work connects oxidized LDL and palmitate uptake to TLR4–LYN–MYD88–NF-κB signaling, while showing that lipid-lowering statins can improve decitabine activity in preclinical models.

• Natural Product Screening for Cryptosporidium AdhE

  2026-10-07

  A source-grounded overview of Cryptosporidium parvum AdhE as a drug-discovery target, the published evidence for imidazole activity, and the appropriate interpretation and limitations of the DiscoveryProbe™ Natural Product Library Plus.

• Molidustat and the Next HIF-PH Translation Frontier

  2026-10-07

  Molidustat (BAY85-3934) illustrates how HIF-PH inhibition can connect oxygen sensing, endogenous erythropoietin stimulation, and chronic kidney disease anemia. This thought-leadership analysis integrates supplier-reported pharmacology with findings from a Septin4–HIF-1α preprint while defining the evidence boundaries that matter for translational research.

• Ibotenic Acid Toxicity in Mice: Dose and Time Effects

  2026-10-06

  Dai et al. provide a systematic in vivo assessment of ibotenic acid toxicity in mice, linking exposure intensity and elapsed time with behavioral changes, biochemical disruption, early c-fos activation, and reduced Nissl staining. The study strengthens the toxicological profile of this NMDA receptor agonist while also defining important boundaries between acute poisoning evidence and broader neuroscience applications.

• Azithromycin in Research: Evidence, Uses, and Limits

  2026-10-06

  A source-critical overview of Azithromycin as a macrolide antibiotic, covering its ribosomal mechanism, bacterial infection research, resistance questions, exploratory animal-model relevance, evidence quality, and key applicability limits.

• Spermine, Ion Channels, and Nuclear Egress

  2026-10-05

  Spermine is an endogenous polyamine with established roles in ion channel regulation, cellular metabolism, and cell growth. This thought-leadership article examines how those mechanisms could inform hypothesis-driven research on CLCC1 and herpesvirus nuclear egress while distinguishing reported findings from forward-looking translational questions.

• Sulfachloropyridazine: Research Context and Evidence

  2026-10-05

  Sulfachloropyridazine is a sulfonamide antibacterial agent studied through DHPS inhibition, antimicrobial susceptibility testing, and microbiome research. This overview examines its mechanistic rationale, reported effects in chickens infected with Eimeria tenella, evidence strength, conceptual applications, and key limitations without treating supplier claims or one animal study as broadly generalizable.

• Brefeldin A: A Causal Map of ER Stress

  2026-10-04

  Brefeldin A is more than a vesicle transport inhibitor: it is a mechanistic probe for separating trafficking failure, ER stress, and cell fate. This article connects BFA research with UBR1/UBR2 protein quality control while defining evidence limits for cancer and cell-biology applications.

• Ferrostatin-1 and Tracheal Epithelial Repair

  2026-10-03

  A 2025 study links ferroptosis in tracheal basal cells with delayed epithelialization of 3D-printed tissue-engineered tracheas. Its main contribution is to connect Fer-1-mediated reduction of oxidative injury with improved cell viability, scaffold epithelial coverage, and reduced granulation tissue in a rabbit model.

• PKM2 Inhibitor (Compound 3k): Assay Logic

  2026-10-01

  PKM2 inhibitor (compound 3k) connects enzyme-level inhibition with cancer metabolism and macrophage reprogramming. This evidence-centered guide explains how to interpret glycolytic, phenotypic, and in vivo findings without overstating preclinical results.

• Ibotenic Acid: From Receptor Biology to Translation

  2026-10-01

  Ibotenic acid is more than a neuroactive reagent: it is a controlled perturbation strategy for testing how glutamatergic signaling becomes circuit dysfunction, neuronal injury, and measurable translational phenotypes. This article connects receptor biology, model selection, toxicology, and product-quality decisions for researchers building reproducible neurodegenerative disease models.

• Homoharringtonine and SARS-CoV-2: Study Evidence

  2026-09-30

  The reference study evaluates homoharringtonine as a translation-targeting intervention against SARS-CoV-2, combining coronavirus cell assays, mouse nasal-delivery experiments, and small human patient cohorts. Its most meaningful contribution is a cross-domain framework linking an established cytotoxic alkaloid with upper respiratory tract antiviral research while also highlighting the evidence gaps that remain before broad clinical use.

• Ibotenic Acid for Circuit Neuroscience Workflows

  2026-09-30

  Ibotenic acid provides a controlled glutamatergic perturbation for circuit dissection, lesion-based neurodegenerative disease models, and causal neuroscience experiments. This guide connects formulation control and histological validation with the brain-to-spinal pain-circuit findings reported in Cell Reports.

• KG-501 Workflows for CREB–KIX Cancer Assays

  2026-09-29

  KG-501 helps separate CREB–coactivator control from downstream macrophage and tumor-cell phenotypes. This guide translates its low-micromolar activity into practical reporter, qPCR, flow-cytometry, and co-culture workflows while clarifying how the compound complements TLR4-focused cancer immunology studies.

8594 records 1/573 page Next 12345 下5页 Last page